OTCMKTS:RSLS

ReShape Lifesciences Competitors

$4.50
+0.35 (+8.43 %)
(As of 04/12/2021 03:03 PM ET)
Add
Compare
Today's Range
$4.33
Now: $4.50
$4.50
50-Day Range
$4.10
MA: $5.02
$7.32
52-Week Range
$1.14
Now: $4.50
$14.00
Volume1,501 shs
Average Volume3,117 shs
Market Capitalization$27.75 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03

Competitors

ReShape Lifesciences (OTCMKTS:RSLS) Vs. ABT, MDT, SYK, ISRG, BDX, and BSX

Should you be buying RSLS stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to ReShape Lifesciences, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Boston Scientific (BSX).

ReShape Lifesciences (OTCMKTS:RSLS) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Valuation and Earnings

This table compares ReShape Lifesciences and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$15.09 million1.84$-74,210,000.00N/AN/A
Abbott Laboratories$31.90 billion6.72$3.69 billion$3.2437.36

Abbott Laboratories has higher revenue and earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-314.18%-186.31%-101.10%
Abbott Laboratories10.50%18.19%8.29%

Insider and Institutional Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for ReShape Lifesciences and Abbott Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences00103.00
Abbott Laboratories111502.82

Abbott Laboratories has a consensus price target of $122.0556, indicating a potential upside of 0.84%. Given Abbott Laboratories' higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than ReShape Lifesciences.

Summary

Abbott Laboratories beats ReShape Lifesciences on 10 of the 12 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLS) and Medtronic (NYSE:MDT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares ReShape Lifesciences and Medtronic's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$15.09 million1.84$-74,210,000.00N/AN/A
Medtronic$28.91 billion5.68$4.79 billion$4.5926.53

Medtronic has higher revenue and earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-314.18%-186.31%-101.10%
Medtronic12.69%9.71%5.30%

Insider & Institutional Ownership

79.2% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for ReShape Lifesciences and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences00103.00
Medtronic031812.91

Medtronic has a consensus price target of $124.2692, indicating a potential upside of 2.04%. Given Medtronic's higher probable upside, analysts clearly believe Medtronic is more favorable than ReShape Lifesciences.

Summary

Medtronic beats ReShape Lifesciences on 11 of the 13 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLS) and Stryker (NYSE:SYK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Insider & Institutional Ownership

71.5% of Stryker shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ReShape Lifesciences and Stryker's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$15.09 million1.84$-74,210,000.00N/AN/A
Stryker$14.88 billion6.37$2.08 billion$8.2630.49

Stryker has higher revenue and earnings than ReShape Lifesciences.

Analyst Recommendations

This is a summary of current recommendations and price targets for ReShape Lifesciences and Stryker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences00103.00
Stryker161412.68

Stryker has a consensus price target of $234.6818, indicating a potential downside of 6.81%. Given Stryker's higher probable upside, analysts clearly believe Stryker is more favorable than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-314.18%-186.31%-101.10%
Stryker12.35%20.94%8.77%

Volatility & Risk

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Summary

Stryker beats ReShape Lifesciences on 11 of the 13 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and ReShape Lifesciences (OTCMKTS:RSLS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Institutional & Insider Ownership

86.5% of Intuitive Surgical shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Intuitive Surgical and ReShape Lifesciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion20.60$1.38 billion$9.9578.32
ReShape Lifesciences$15.09 million1.84$-74,210,000.00N/AN/A

Intuitive Surgical has higher revenue and earnings than ReShape Lifesciences.

Profitability

This table compares Intuitive Surgical and ReShape Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
ReShape Lifesciences-314.18%-186.31%-101.10%

Analyst Ratings

This is a summary of current ratings and price targets for Intuitive Surgical and ReShape Lifesciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical381102.36
ReShape Lifesciences00103.00

Intuitive Surgical presently has a consensus price target of $750.9444, indicating a potential downside of 3.63%. Given Intuitive Surgical's higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than ReShape Lifesciences.

Volatility & Risk

Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Summary

Intuitive Surgical beats ReShape Lifesciences on 10 of the 12 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and ReShape Lifesciences (OTCMKTS:RSLS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Becton, Dickinson and and ReShape Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
ReShape Lifesciences-314.18%-186.31%-101.10%

Volatility & Risk

Becton, Dickinson and has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Becton, Dickinson and and ReShape Lifesciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and06702.54
ReShape Lifesciences00103.00

Becton, Dickinson and currently has a consensus price target of $281.5455, indicating a potential upside of 13.80%. Given Becton, Dickinson and's higher probable upside, equities research analysts plainly believe Becton, Dickinson and is more favorable than ReShape Lifesciences.

Institutional and Insider Ownership

83.2% of Becton, Dickinson and shares are held by institutional investors. 0.8% of Becton, Dickinson and shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Becton, Dickinson and and ReShape Lifesciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion4.20$874 million$10.2024.26
ReShape Lifesciences$15.09 million1.84$-74,210,000.00N/AN/A

Becton, Dickinson and has higher revenue and earnings than ReShape Lifesciences.

Summary

Becton, Dickinson and beats ReShape Lifesciences on 10 of the 12 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLS) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ReShape Lifesciences and Boston Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences00103.00
Boston Scientific041512.85

Boston Scientific has a consensus target price of $43.20, indicating a potential upside of 9.81%. Given Boston Scientific's higher probable upside, analysts clearly believe Boston Scientific is more favorable than ReShape Lifesciences.

Valuation & Earnings

This table compares ReShape Lifesciences and Boston Scientific's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$15.09 million1.84$-74,210,000.00N/AN/A
Boston Scientific$10.74 billion5.21$4.70 billion$1.5824.90

Boston Scientific has higher revenue and earnings than ReShape Lifesciences.

Institutional & Insider Ownership

90.7% of Boston Scientific shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ReShape Lifesciences and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-314.18%-186.31%-101.10%
Boston Scientific36.59%11.77%5.57%

Risk & Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Summary

Boston Scientific beats ReShape Lifesciences on 11 of the 13 factors compared between the two stocks.


ReShape Lifesciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$121.04+0.1%$214.43 billion$31.90 billion64.04Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$121.79+0.2%$164.18 billion$28.91 billion46.48
Stryker logo
SYK
Stryker
2.0$251.83+0.6%$94.77 billion$14.88 billion54.63Insider Selling
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$779.26+0.7%$92.25 billion$4.48 billion88.75Upcoming Earnings
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.2$247.41+0.2%$71.89 billion$17.12 billion90.63
Boston Scientific logo
BSX
Boston Scientific
1.8$39.34+0.1%$55.88 billion$10.74 billion15.07
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.4$85.82+0.2%$53.38 billion$4.35 billion68.66Upcoming Earnings
Insider Selling
News Coverage
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$506.43+0.7%$43.37 billion$2.41 billion88.23
Baxter International logo
BAX
Baxter International
1.9$84.54+0.4%$42.70 billion$11.36 billion48.03
DexCom logo
DXCM
DexCom
1.9$387.15+1.1%$37.23 billion$1.48 billion159.98
ResMed logo
RMD
ResMed
1.5$201.74+1.3%$29.35 billion$2.96 billion43.29
Teleflex logo
TFX
Teleflex
1.8$426.29+0.2%$19.93 billion$2.60 billion54.86Decrease in Short Interest
News Coverage
Hologic logo
HOLX
Hologic
1.9$74.42+1.1%$19.18 billion$3.78 billion17.72
Insulet logo
PODD
Insulet
1.4$284.72+0.8%$18.81 billion$738.20 million647.11
STERIS logo
STE
STERIS
2.1$200.62+0.7%$17.12 billion$3.03 billion40.69Increase in Short Interest
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.12+0.1%$16.27 billion$3.17 billion60.45News Coverage
Abiomed logo
ABMD
Abiomed
1.4$333.11+0.2%$15.07 billion$840.88 million73.21
Masimo logo
MASI
Masimo
1.6$234.71+0.2%$12.97 billion$937.84 million60.96Insider Selling
Hill-Rom logo
HRC
Hill-Rom
1.8$112.02+0.8%$7.43 billion$2.88 billion33.74Insider Selling
Increase in Short Interest
Globus Medical logo
GMED
Globus Medical
1.4$67.57+0.8%$6.74 billion$785.37 million73.45News Coverage
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.44+1.0%$5.86 billion$1.52 billion103.64Insider Selling
NuVasive logo
NUVA
NuVasive
1.1$68.43+0.4%$3.52 billion$1.17 billion-311.05
Integer logo
ITGR
Integer
1.6$91.71+1.0%$3.02 billion$1.26 billion41.69
AtriCure logo
ATRC
AtriCure
1.5$65.83+0.1%$3.00 billion$230.81 million-57.24Analyst Report
News Coverage
Alphatec logo
ATEC
Alphatec
0.8$17.10+2.9%$1.63 billion$113.43 million-15.55Insider Selling
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.74+1.7%$1.48 billion$236.54 million-55.67
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.34+1.8%$890.12 million$264.16 million-5.22Decrease in Short Interest
CryoLife logo
CRY
CryoLife
2.0$22.48+0.6%$879.42 million$276.22 million-59.16News Coverage
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.05+2.0%$820.48 million$459.95 million35.04
Surmodics logo
SRDX
Surmodics
1.3$57.03+0.2%$784.51 million$94.86 million712.88News Coverage
Accuray logo
ARAY
Accuray
2.3$5.18+0.6%$481.21 million$382.93 million37.00
Invacare logo
IVC
Invacare
1.6$8.41+1.7%$289.51 million$927.96 million-6.84
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.98+6.1%$92.13 million$61.30 million-2.29
Navidea Biopharmaceuticals logo
NAVB
Navidea Biopharmaceuticals
1.7$1.74+9.2%$49.71 million$660,000.00-3.35Increase in Short Interest
Gap Down
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10+90.1%$38.87 million$40,000.000.00Gap Up
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.